Patents by Inventor Yuko Shinagawa
Yuko Shinagawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20160137639Abstract: A compound represented by Formula [I]: or pharmaceutically acceptable salt thereof, wherein each symbol is as defined in the description.Type: ApplicationFiled: October 25, 2013Publication date: May 19, 2016Inventors: Masayuki KOTOKU, Takaki MAEBA, Noriyoshi SEKI, Shintaro HIRASHIMA, Shingo FUJIOKA, Shingo OBIKA, Hiroshi YAMANAKA, Masahiro YOKOTA, Takayuki SAKAI, Kazuyuki HIRATA, Katsuya MAEDA, Makoto SHIOZAKI, Yuko SHINAGAWA, Taku IKENOGAMI, Satoki DOI, Takahiro OKA, Takuya MATSUO, Yoshihiro SUWA, Keisuke ITO, Satoru NOJI, Yoshinori HARA
-
Publication number: 20120301552Abstract: A compound represented by the following formula (1), a pharmaceutically acceptable salt thereof or an optically active form thereof: wherein each symbol is as defined in the specification. A compound having a calcium-sensing receptor antagonistic action, a pharmaceutical composition comprising the compound, particularly a calcium receptor antagonist and a therapeutic drug for osteoporosis are provided.Type: ApplicationFiled: December 23, 2011Publication date: November 29, 2012Applicant: JAPAN TOBACCO INC.Inventors: Yuko Shinagawa, Teruhiko Inoue, Toshihiro Kiguchi, Taku Ikenogami, Naoki Ogawa, Kenji Fukuda, Takashi Nakagawa, Masanori Shindo, Yuki Soejima
-
Publication number: 20100286416Abstract: The present invention provides the production method of carboxylic acid compound, as shown in Scheme I.Type: ApplicationFiled: March 26, 2010Publication date: November 11, 2010Applicant: Japan Tobacco Inc.Inventors: Katsuya Matsumoto, Katsuyuki Yokota, Yuko Shinagawa, Teruhiko Inoue
-
Publication number: 20090326058Abstract: A compound represented by the following formula (1), a pharmaceutically acceptable salt thereof or an optically active form thereof: wherein each symbol is as defined in the specification. A compound having a calcium-sensing receptor antagonistic action, a pharmaceutical composition comprising the compound, particularly a calcium receptor antagonist and a therapeutic drug for osteoporosis are provided.Type: ApplicationFiled: March 27, 2009Publication date: December 31, 2009Applicant: JAPAN TOBACCO INC.Inventors: YUKO SHINAGAWA, TERUHIKO INOUE, TOSHIHIRO KIGUCHI, TAKU IKENOGAMI, NAOKI OGAWA, KENJI FUKUDA, TAKASHI NAKAGAWA, MASANORI SHINDO, YUKI SOEJIMA
-
Publication number: 20080255042Abstract: A compound represented by the following formula (1), a pharmaceutically acceptable salt thereof or an optically active form thereof: wherein each symbol is as defined in the specification. A compound having a calcium-sensing receptor antagonistic action, a pharmaceutical composition comprising the compound, particularly a calcium receptor antagonist and a therapeutic drug for osteoporosis are provided.Type: ApplicationFiled: August 17, 2007Publication date: October 16, 2008Applicant: JAPAN TOBACCO INC.Inventors: Yuko Shinagawa, Teruhiko Inoue, Toshihiro Kiguchi, Taku Ikenogami, Naoki Ogawa, Kenji Fukuda, Takashi Nakagawa, Masanori Shindo, Yuki Soejima
-
Publication number: 20080064871Abstract: [Problems] The present invention provides a superior production method and a superior purification method of compounds effective for the treatment or prophylaxis of pathology showing involvement of uric acid, such as hyperuricemia, gouty tophus, acute gouty arthritis, chronic gouty arthritis, gouty kidney, urolithiasis, renal function disorder, coronary artery disease, ischemic heart disease and the like. [Means] A compound represented by the following formula [2] or a pharmaceutically acceptable salt thereof can be produced by reacting a compound represented by the following formula [3] or a salt thereof with a compound represented by the following formula [4], a salt thereof or a reactive derivative thereof. Moreover, crystallization of a compound represented by the formula [2] can be performed with industrially superior workability, and high quality crystals of a compound represented by the formula [2] can be obtained. wherein each symbol is as defined in the description.Type: ApplicationFiled: May 24, 2007Publication date: March 13, 2008Applicant: Japan Tobacco Inc.Inventors: Kazuyuki Hirata, Naoki Ogawa, Yuko Shinagawa, Toshihiro Kiguchi, Teruhiko Inoue, Yasuki Komeda, Ichiro Yamashita, Yukihiro Kamiya
-
Patent number: 7304174Abstract: A compound represented by the following formula (1), a pharmaceutically acceptable salt thereof or an optically active form thereof: wherein each symbol is as defined in the specification. A compound having a calcium-sensing receptor antagonistic action, a pharmaceutical composition comprising the compound, particularly a calcium receptor antagonist and a therapeutic drug for osteoporosis are provided.Type: GrantFiled: April 23, 2004Date of Patent: December 4, 2007Assignee: Japan Tobacco Inc.Inventors: Yuko Shinagawa, Teruhiko Inoue, Toshihiro Kiguchi, Taku Ikenogami, Naoki Ogawa, Kenji Fukuda, Takashi Nakagawa, Masanori Shindo, Yuki Soejima
-
Patent number: 7285572Abstract: The present invention provides a compound having a calcium-sensitive receptor antagonistic action, a pharmaceutical composition containing the compound, particularly a calcium receptor antagonist and a therapeutic drug for osteoporosis. A compound represented by the following formula (1), a pharmaceutically acceptable salt thereof or an optically active form thereof: wherein each symbol is as defined in the description.Type: GrantFiled: November 25, 2005Date of Patent: October 23, 2007Assignee: Japan Tobacco Inc.Inventors: Yuko Shinagawa, Teruhiko Inoue, Toshihiro Kiguchi, Taku Ikenogami, Naoki Ogawa, Takashi Nakagawa, Masanori Shindo, Yuki Soejima
-
Publication number: 20070197512Abstract: Provision of a superior URAT1 activity inhibitor effective for the treatment and the like of a pathology involving uric acid, such as hyperuricemia, gouty tophus, acute gouty arthritis, chronic gouty arthritis, gouty kidney, urinary lithiasis, renal dysfunction, coronary heart disease, ischemic cardiac diseases and the like. A URAT1 activity inhibitor containing a compound represented by the following formula [1] or a pharmaceutically acceptable salt thereof, or a solvate thereof as an active ingredient: wherein each symbol is as defined in the specification.Type: ApplicationFiled: January 26, 2007Publication date: August 23, 2007Applicant: Japan Tobacco Inc.Inventors: Teruhiko Inoue, Toshihiro Kiguchi, Kazuyuki Hirata, Yuko Shinagawa, Naoki Ogawa, Katsuya Deai
-
Patent number: 7211685Abstract: A compound of the formula [I] wherein R1 is optionally substituted aryl group or optionally substituted heteroaryl group; R2 is optionally substituted C1-6 alkyl group, C3-7 cycloalkyl group and the like; R3 is hydrogen atom, C1-6 alkyl group, hydroxyl group and the like; R4 is hydrogen atom, C1-6 alkyl group and the like; R5 and R6 are each C1-6 alkyl group and the like; R7 is optionally substituted aryl group or optionally substituted heteroaryl group; X1, X2 and X3 are each C1-6 alkylene group and the like; and X4 and X5 are each a single bond, methylene group and the like, a salt thereof, a solvate thereof or a prodrug thereof, and a pharmaceutical composition containing the compound, particularly a calcium receptor antagonist and a therapeutic agent for osteoporosis, are provided.Type: GrantFiled: November 12, 2004Date of Patent: May 1, 2007Assignee: Japan Tobacco Inc.Inventors: Yuko Shinagawa, Takeo Katsushima, Takashi Nakagawa
-
Publication number: 20070010670Abstract: A URAT1 activity inhibitor containing a nitrogen-containing fused ring compound represented by the following formula [1]: wherein each symbol is as defined in the description. The present invention is useful for the prophylaxis or treatment of pathology showing involvement of uric acid, such as hyperuricemia, gouty tophus, acute gouty arthritis, chronic gouty arthritis, gouty kidney, urolithiasis, renal function disorder, coronary artery disease, ischemic heart disease and the like.Type: ApplicationFiled: November 29, 2005Publication date: January 11, 2007Applicant: Japan Tobacco Inc.Inventors: Kazuyuki Hirata, Naoki Ogawa, Yuko Shinagawa, Toshihiro Kiguchi, Teruhiko Inoue, Akira Matsuo, Yoshinori Kosugi, Yukihiro Nomura, Iichiro Kawahara, Hideto Uehara
-
Publication number: 20060135572Abstract: The present invention provides a compound having a calcium-sensitive receptor antagonistic action, a pharmaceutical composition containing the compound, particularly a calcium receptor antagonist and a therapeutic drug for osteoporosis. A compound represented by the following formula (1), a pharmaceutically acceptable salt thereof or an optically active form thereof: wherein each symbol is as defined in the description.Type: ApplicationFiled: November 25, 2005Publication date: June 22, 2006Applicant: JAPAN TOBACCO INC.Inventors: Yuko Shinagawa, Teruhiko Inoue, Toshihiro Kiguchi, Taku Ikenogami, Naoki Ogawa, Takashi Nakagawa, Masanori Shindo, Yuki Soejima
-
Patent number: 6916956Abstract: A compound of the formula [I] wherein R1 is optionally substituted aryl group or optionally substituted heteroaryl group; R2 is optionally substituted C1-6 alkyl group, C3-7 cycloalkyl group and the like; R3 is hydrogen atom, C1-6 alkyl group, hydroxyl group and the like; R4 is hydrogen atom, C1-6 alkyl group and the like; R5 and R6 are each C1-6 alkyl group and the like; R7 is optionally substituted aryl group or optionally substituted heteroaryl group; X1, X2 and X3 are each C1-6 alkylene group and the like; and X4 and X5 are each a single bond, methylene group and the like, a salt thereof, a solvate thereof or a prodrug thereof, and a pharmaceutical composition containing the compound, particularly a calcium receptor antagonist and a therapeutic agent for osteoporosis, are provided.Type: GrantFiled: August 10, 2001Date of Patent: July 12, 2005Assignee: Japan Tobacco, Inc.Inventors: Yuko Shinagawa, Takeo Katsushima, Takashi Nakagawa
-
Publication number: 20050107448Abstract: A compound of the formula [I] wherein R1 is optionally substituted aryl group or optionally substituted heteroaryl group; R2 is optionally substituted C1-6 alkyl group, C3-7 cycloalkyl group and the like; R3 is hydrogen atom, C1-6 alkyl group, hydroxyl group and the like; R4 is hydrogen atom, C1-6 alkyl group and the like; R5 and R6 are each C1-6 alkyl group and the like; R7 is optionally substituted aryl group or optionally substituted heteroaryl group; X1, X2 and X3 are each C1-6 alkylene group and the like; and X4 and X5 are each a single bond, methylene group and the like, a salt thereof, a solvate thereof or a prodrug thereof, and a pharmaceutical composition containing the compound, particularly a calcium receptor antagonist and a therapeutic agent for osteoporosis, are provided.Type: ApplicationFiled: November 12, 2004Publication date: May 19, 2005Inventors: Yuko Shinagawa, Takeo Katsushima, Takashi Nakagawa
-
Publication number: 20050032796Abstract: A compound represented by the following formula (1), a pharmaceutically acceptable salt thereof or an optically active form thereof: wherein each symbol is as defined in the specification. A compound having a calcium-sensing receptor antagonistic action, a pharmaceutical composition comprising the compound, particularly a calcium receptor antagonist and a therapeutic drug for osteoporosis are provided.Type: ApplicationFiled: April 23, 2004Publication date: February 10, 2005Inventors: Yuko Shinagawa, Teruhiko Inoue, Toshihiro Kiguchi, Taku Ikenogami, Naoki Ogawa, Kenji Fukuda, Takashi Nakagawa, Masanori Shindo, Yuki Soejima
-
Publication number: 20040006130Abstract: A compound of the formula [I] 1Type: ApplicationFiled: February 10, 2003Publication date: January 8, 2004Inventors: Yuko Shinagawa, Takeo Katsushima, Takashi Nakagawa